Saclipin A and saclipin B are bioactive oxylipin compounds derived from an edible cyanobacterium, Aphanothece sacrum. Saclipins have been shown to have potent anti-aging properties, including antioxidative, antiglycative, anti-wrinkle, and skin-whitening activities. In this study, we demonstrate that the anti-collagenase and anti-hyaluronidase activities of saclipins are additional anti-wrinkle properties of these compounds. Furthermore, we reveal that saclipins exert angiotensin-converting enzyme (ACE) inhibitory activities, which can mitigate hypertension. These results suggest that saclipins are promising natural products with applications not only for skincare products but also as medical supplements.
Rheumatoid arthritis is a chronic systemic autoimmune disease that affects the synovial joints. Low-level laser photobiomodulation (LLLT) has microcirculatory, analgesic, and anti-inflammatory effects. In this paper, the percentage of collagen fibrils and IL-6 protein expression in the synovia were measured to evaluate the effects of photobiomodulation (PBM) with LLLT (λ = 808 nm) on the morphology. Eighteen female Wistar rats were assigned into three groups: Control, Sham, and PBM. To induce arthritis, animals from the Sham and PBM groups received one intraarticular dose of zymosan (200 µg) under anesthesia. Twenty-four hours after induction, an LLLT treatment (λ = 808 nm, 25 mW nominal power, fluence of 20J/cm2, beam area of 0.02 mm2, time of 33 s, total energy of 0.825 J) was applied. Seven days after induction, samples from the animals' knees were subjected to histological and morphometric analyses, and the percentage of collagen fibers in the synovial area (% total area) with and without polarized light and IL-6 protein expression were measured by immunohistochemistry. Statistical analyses were performed an ANOVA and Tukey's post-test with p < 0.05 to compare the experimental groups using. Inflammation of the synovial region showed significant differences between Sham vs. Control, p < 0.0001, and PBM vs. Sham, p < 0.001. The areas of collagen fibers (total percentage) showed differences between Sham vs. Control, p < 0.0001, and Sham vs. PBM, p = 0.0149. IL-6 showed differences between Sham vs. Control and PBM vs. Sham, p < 0.001. Treatment with PBM using LLLT showed decreased synovial inflammation, collagen fiber formation, fibrosis, and IL-6 protein expression, and consequently decreased joint degradation.
Euphorbia thymifolia Linn is a medicinal plant widely used in traditional Asian medicine due to its bioactive constituents, which exhibit antioxidant, antimicrobial, antifungal, anticancer, and especially, antityrosinase activities. The aim of this study was to assess the antioxidant capacity, antityrosinase activity, and melanin inhibition potential of E. thymifolia L. extract and a serum prototype containing 2% of the extract. Antioxidant activity was assessed using the 2,2-diphenyl-1-picrylhydrazyl (DPPH), 2,2′-azino-bis-(3-ethylbenzothiazoline-6-sulfonic) acid (ABTS) radical scavenging capacity, and ferric reducing antioxidant power (FRAP) assays. Melanin production inhibition and cytotoxicity of the extract and serum were investigated using the B16-F10 mouse melanoma cell line. The E. thymifolia L. extract scavenged free radicals, with half-maximal inhibitory concentration (IC50) values of 63.50 µg/mL in the DPPH assay and 168.55 µg/mL in the ABTS assay, and concentration at absorbance 0.5 (Abs0.5) values of 90.99 µg/mL in the FRAP assay. Both the extract and the serum showed significant antityrosinase activity, with IC50 values of 3.92 and 14.07 µg/mL, respectively. Moreover, the extract and serum inhibited melanin production in B16-F10 melanoma cells by 26.35% and 27.23%, respectively, at a concentration of 20 µg/mL, with relatively low cytotoxicity (46.33% and 46.87%, respectively) even at the high concentration of 100 µg/mL. The developed serum had a pH of 6.17 and high uniformity and was nontoxic to melanocytes. These promising results concerning the beneficial activities of the E. thymifolia extract and serum containing the extract suggest that this medicinal plant may be a potential source for the development of pharmaceutical and cosmetic products.
Curcumin (CUR) a natural polyphenolic compound, has attracted significant attention due to its broad-spectrum anti-inflammatory, antioxidant, antimicrobial, and antitumor activities. However, its poor water solubility, low bioavailability, and limited stability have hindered clinical applications. Novel approaches utilizing nanocarrier-based delivery systems (e.g., liposomes, micelles) and structural modification strategies offer promising solutions to enhance the therapeutic efficacy of curcumin. This review and analysis attempted to summarize the therapeutical applications and working mechanisms of CUR in oral infectious diseases, inflammation, traumatic disease and immune disorder. Publications included in this review included references were confined to curcumin, nano-curcumin (nCUR), and the names of different oral diseases; the different methodologies included clinical trials, in vivo animal studies and in vitro studies. Web of Science and Pubmed/MEDLINE databases were explored. The antioxidant, anti-inflammatory, immune regulation and anticancer properties of CUR and nCUR are reported, and their positive applications in oral diseases is discussed. With more favorable structure and improved solubility and bioavailability, nCUR is more beneficial, stable and efficient than CUR. Local application seems to be more effective on oral diseases, which allows for higher concentrations and better bioavailability, and can directly targets specific areas of the mouth, providing more precise treatment. Both CUR and nCUR are likely to be developed into a next-generation drug, but there is no consensus on their concentration, irradiation times and light intensity. Additional trials are required to obtain clinical standards, and establish specific dose ranges and clinical procedures.
The recurrence of bacterial infections is commonly associated with the multiple interactions between humans and their environment. These interactions have progressively contributed to the development of antimicrobial resistance among numerous clinically important pathogenic bacteria. The present study targeted the antibacterial activity of natural products derived from the stem bark of O. subscorpioidea against clinical isolates of bacteria. This included the Gram-positive bacterium Staphylococcus aureus and three Gram-negative bacteria, Pseudomonas aeruginosa, Providencia stuartii,and Escherichia coli.The plant material was extracted by maceration, and chromatography was performed to isolate the chemical constituents from plant extracts as well as from the reaction medium. The resulting compounds were characterized using spectroscopic and spectrometric techniques. The antibacterial activity was assessed by the microdilution method. Five compounds were isolated, including olasubscorpioside A (1), 4´- O-methylgallocatechin (2), olasubscorpioside C (3), olasubscorpioside B (5a), isoolasubcorpioside B (5b), and glyceryl-1-eicosanoate (6). The semisynthetic derivatives 4΄- O-methylgallocatechin (2) (also isolated from the plant extract) and tetra- O-allyl olasubscorpioside A (4) were prepared and characterized. Interestingly, olasubscorpioside A (1) and 4΄- O-methylgallocatechin (2) displayed a significant antibacterial effect (MIC = 8 µg/mL) against the pathogenic isolate Staphylococcus aureus resistant to methicillin, ofloxacin, kanamycin, tetracycline, and erythromycin. Compound 2 had a better activity relative to 1 against Pseudomonas aeruginosa(from MIC > 256 to 128 µg/mL) and Escherichia coli(from MIC = 128 to 64 µg/mL). Gallocatechins from the stem bark of Olax subscorpioideaare promising bioactive molecules to fight against multiresistant bacteria.
AMPK-1α is a master energy sensor that phosphorylates more than 100 client proteins involved in almost all branches of cellular metabolism. We recently demonstrated that weak mTORC1 (mTORC1Weak) signaling promotes the differentiation of pro-survival cytokine IL-7- or IL-15- stimulated CD8+memory T (IL-7/TM and IL-15/TM) cells derived from ovalbumin (OVA)-specific T- cell receptor transgenic OTI mice by upregulating the expression of AMPK-1α and another twelve autophagic and metabolic regulators, including ULK1, ATG7, LC3II, SIRT1, PGC1α, CPT1α, AQP9, Complex I, LAL, OPA1, Bcl6, and TFAM. To investigate the potential role of AMPK-1α in controlling the abundance of these proteins, we genetically engineered AMPK knockout (KO)/OTI mice, and then prepared and subjected IL-7/TM or IL-15/TM cells from these animals to western blot analyses. Interestingly, we found that their steady-state levels were all significantly down-regulated in both IL- 7/TM and IL-15/TM cells upon the loss of AMPK-1α expression. Thus, our data suggest that AMPK- 1α indeed regulates these 12 downstream targets, a possibility that is further substantiated by the fact that a modern chemical genetic screen previously identified ULK1, ATG7, LC3II, SERT1, and PGC1α as AMPK-1α substrates. Taken together, our data establishes that the master energy sensor AMPK-1α controls the expression of seven additional regulatory markers, which are all critical to cellular metabolism and whose identification may impact the development of AMPK-1α-targeted therapeutics for treating metabolic disorders and cancer diseases.